Trimetazidine Hydrochloride is the new twice-daily formulation of the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients. Trimetazidine inhibits fatty acid pathway by inhibiting 3-ketoacylCoA thiolase enzyme and transfers oxygen to glucose pathway.Since glucose pathway is more efficient in producing energy, the same oxygen produces more energy and makes the heat more active. Moreover, the aerobic oxidation of glucose stops production of lactic acid, which prevents angina pectoris.
Presntation:
Metacard MR Tablet: Each modified release tablet contains Trimetazidine Hydrochloride BP 35 mg.
Indications:
Metacard MR Tablet is a metabolic treatment for ischaemic heart disease. It can be used at all stages of angina pectoris and in post myocardial infarction. Metacard MR therapy has also demonstrated beneficial effects when administered during bypass surgery.
Dosage & Administration:
The recommended dose of Metacard MR (Trimetazidine) is 35 mg twice daily or 20 mg tablet thrice daily during meals. The benefit of the treatment should be assessed after three months and Trimetazidine should be discontinued if there is no treatment response
